市場調查報告書
商品編碼
1417598
全球眼科雷射市場評估:依產品類型、應用、最終用戶、地區、機會、預測(2017-2031)Ophthalmic Lasers Market Assessment, By Product Type, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
全球眼科雷射市場規模預計到2023年將達到15.1億美元,到2031年將達到23.8億美元,2024-2031年預測期間複合年增長率為5.86%。全球眼科雷射市場是眼科器械市場中成長最快的市場。全球眼科雷射市場受到眼科疾病盛行率增加、老年人口增加以及雷射設備技術進步等因素的推動。由於螢幕時間增加、生活方式改變、營養缺乏和慢性疾病等因素,全球眼科患者數量不斷增加。這些因素推動了對眼科雷射設備的巨大需求。
預計老齡化人口的成長將增加有視力障礙需求的人數。此外,由於眼科疾病是慢性病的主要合併症,糖尿病和高血壓等慢性病的盛行率不斷上升,預計將吸引雷射設備的需求。許多技術進步,例如設計優化、功能改進和副作用減少,都有助於眼科雷射設備不斷增長的需求。政府的利好政策加強了醫療基礎設施和設備的供應,促進了市場。與傳統治療相比,雷射眼科治療具有多種優勢,包括疼痛少、療效高、住院時間短、無需切口等,使其成為治療白內障、AMD、青光眼等眼部疾病的理想選擇,深受人們喜愛。然而,雷射治療成本高昂且缺乏熟練專業人員等因素可能會阻礙預測期內的市場成長。
2023 年 4 月,Johnson & Johnson Vision 宣布其新型 ELITA Femtosecond Laser已獲得 FDA 510(k) 許可。過去 20 年來,Johnson & Johnson Vision 一直是眼科設備產業的領導者,擁有前景看好的產品組合。ELITA Femtosecond Laser具有低每脈衝能量、超快雷射重複率和小光斑尺寸,提高了外科醫生的速度和準確性。
由於不健康的生活方式、營養缺乏和長時間看螢幕,眼科疾病的盛行率不斷上升,推動了眼科雷射市場的需求。最常見的眼部疾病包括近視、屈光不正、白內障、糖尿病視網膜病變、青光眼和老年黃斑部病變。大多數外科醫生建議針對這些情況進行雷射治療,因為它已被證明是有效的並且需要較少的術後護理。
例如,根據世界衛生組織2023年8月發布的情況說明書,全球約有22億人患有近視力障礙或遠視力障礙,其中約10億人患有遠視力障礙;8840萬人因白內障失明, 8840萬人患有屈光不正,800萬人患有老年黃斑部病變,770萬人患有青光眼,390萬人患有糖尿病性視網膜病變。近距離視力障礙的主要原因是老花眼,影響約 8.26 億人。
老化人口的增加,更容易患上眼部疾病,大大推動了對眼科雷射治療的需求。隨著年齡的增長,與年齡相關的因素導致眼部疾病的可能性也會增加。日本等國家老年人口較多,因此佔了很大一部分市場。根據世界衛生組織的數據,到2030年,全球總人口將達到14億,六分之一的人將年齡在60歲以上。世界衛生組織估計,到 2020 年,老年人口將達到 10 億。預計到 2050 年,這一數字將增加一倍。從2020年到2050年,80歲及以上的人口預計將增加四倍,達到約4.26億人。根據國家健康與老化趨勢研究,美國 71 歲及以上的成年人中有 27.8% 有視力障礙。
本報告針對全球眼科雷射市場進行研究和分析,提供市場規模和預測、市場動態、主要參與者現狀和前景等。
Global ophthalmic lasers market size was valued at USD 1.51 billion in 2023, and is expected to reach USD 2.38 billion in 2031, with a CAGR of 5.86% for the forecast period between 2024 and 2031F. The global ophthalmic lasers market is a fast-growing market within the ophthalmic devices market. The global ophthalmic lasers market is driven by factors such as the growing prevalence of ophthalmic disorders, rising geriatric population, and technological advancements in laser devices. The number of ophthalmic patients is increasing globally owing to factors such as longer screen time, lifestyle changes, lack of nutrition, and chronic diseases. These factors are driving huge demand for ophthalmic laser devices.
Growth in geriatric population is expected to increase the number of people who require vision impairment. Additionally, the growing prevalence of chronic diseases, such as diabetes and hypertension, are expected to draw demand for laser devices as ophthalmic disorders are prominent comorbidities with chronic diseases. Technological advancements like design optimization, functionality improvement, reducing side effects, and many others are favoring the growth in demand for ophthalmic laser devices. Favorable government policies strengthen the healthcare infrastructure and medical device availability, promoting the market. Laser ophthalmic treatments have several benefits over conventional treatment methods such as less pain, high effectivity, shorter hospital stay, and no need for incision, thus preferred over conventional methods for managing ophthalmic diseases like cataracts, AMD, and glaucoma. However, factors like the high cost of laser therapies and the lack of skilled professionals may hinder market growth during the forecast period.
In April 2023, Johnson & Johnson Vision announced that it had received FDA 510(k) clearance for its new ELITA Femtosecond Laser FDA 510(k) clearance to create LASIK flaps. Johnson & Johnson Vision has been a leader in the ophthalmic devices industry for the last two decades with a promising product portfolio. The ELITA Femtosecond laser flap offers low energy per pulse, with ultra-fast laser repetition rate and small spot size, facilitating the surgeon's speed and accuracy.
The growing prevalence of ophthalmic disorders due to unhealthy lifestyles, nutritional deficiency, and longer screen time is driving the demand in the ophthalmic lasers market. Most common ophthalmic disorders include myopia, refractive errors, cataracts, diabetic retinopathy, glaucoma, and age-related macular degeneration. Most surgeons recommend laser treatments for such diseases as they are proven effective and require a shorter post-operative care period.
For instance, according to a factsheet published by WHO in August 2023, around 2.2 billion individuals are suffering from near or distance vision impairment across the globe, out of which approx. 1 billion people suffer from distance vision impairment, 1 billion from blindness with cataracts, 88.4 million from refractive error, 8 million from age-related macular degeneration, 7.7 million from glaucoma, and 3.9 million from diabetic retinopathy. The major defect causing near vision impairment is presbyopia with a number of around 826 million patients.
The growing geriatric population that is highly prone to ophthalmic disorders is significantly driving the demand for ophthalmic laser treatments. With age, the chances of ophthalmic diseases increase due to age-associated factors. Countries such as Japan have a very high number of old age individuals and thus are contributing a major chunk of value share to the market. As per WHO data, by 2030, 1 out of 6 individuals worldwide will be above the age of 60 years, which is expected to be 1.4 billion population in total. WHO estimated 1 billion geriatric population in 2020. The number is expected to double (to 2.1 billion) by 2050. It is anticipated that between 2020 and 2050, the number of people 80 years of age or older will quadruple, reaching approx. 426 million counts. According to the National Health and Aging Trends Study, 27.8% of United States adults 71 years and older had visual impairments.
The femtosecond laser segment in global ophthalmic lasers is expected to dominate during the forecast period. Femtosecond laser is highly effective for the treatment of cataracts and refractive errors in the eye and, thus, is very commonly used. The growing prevalence of cataracts and technological advancements in femtosecond laser devices are some reasons for their dominance. Market players are investing in femtosecond laser technology to add cutting-edge products to their portfolio. For instance, in February 2023, Fluence announced the launch of Jasper Micro, a new addition to its Jasper range of femtosecond lasers. Jasper Micro is an air-cooled and very compact device with widespread applications like LASIK, PRK, and DNA transfection eye surgeries.
Asia-Pacific is home to developing countries, like India and China, which have a significantly high burden of ophthalmic diseases. The rising geriatric population with a higher affinity to ophthalmic diseases is driving the demand for ophthalmic lasers. The growing investment in the healthcare sector is helping expand the associated markets. Increasing investors' attention towards the region is opening opportunities for market expansion. Demand for efficient ophthalmic equipment in Asia-Pacific is increasing owing to rapidly evolving technologies. Heavy emphasis on preventive care and early intervention for ophthalmic disorders fuels the demand for ophthalmic lasers during the assessment period.
The healthcare infrastructure is developing and getting strengthened in nations across the globe and multiple attempts are being made to reduce the burden of ophthalmic diseases, for example, the integrated people-centered eye care (IPEC) initiative by WHO. Noval technology penetration in ophthalmic laser devices such as developments in femtosecond laser technology, the use of wavefront technology, and the use of adaptive optics are anticipated to strengthen the market dynamics in future years. These advances are anticipated to help surgeons perform more intricate and precise surgeries in the future through highly evolved lasers.
Market players are expanding their product offerings and giving their customers access to a wide range of cutting-edge and novel products using a variety of strategies. To gain market share, companies are expanding their range of products being offered. Industry participants use various growth methods, including collaborations, mergers and acquisitions, product launches, and development of new products, to bolster their positions in the market.
In December 2023, Carl Zeiss Meditec AG announced the agreement to acquire 100% shares of the Dutch Ophthalmic Research Center (DORC) from the France-based investment firm Eurazeo. The deal is valued at EUR 985 million and is expected to close in the first half of 2024. DORC's offer robust portfolio includes devices, disposables, and liquids for ophthalmic surgeries, with prime focus on its dual-function Eva Nexustm platform.
All segments will be provided for all regions and countries covered:
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.